Celgene’s Otezla Fails To Meet Primary Endpoint In Phase 3 Study

July 9, 2014 7:23 PM

8 0

Celgene’s Otezla Fails To Meet Primary Endpoint In Phase 3 Study

Celgene’s Phase 3 study of Otezla, an oral inhibitor for treating spondylitis, did not meet its primary target, causing the company’s stock to open around 3% lower today

Celgene Corporation (CELG) opened in the red today, on news that the company failed to meet the primary endpoint in phase 3 POSTURE study for Otezla—an oral inhibitor of phosphodiesterase 4 (PDE4) for the treatment of ankylosing spondylitis.

Also read: Synergy Pharma's irritable bowel drug succeeds in key study

Read more

To category page

Loading...